Assess Biomarkers of Tobacco Exposure and Nicotine Pharmacokinetics in Smokers After a 5-Day In-Clinic Confinement Switch to an Electronic Cigarette or Nicotine Gum

NCT ID: NCT02323438

Last Updated: 2018-06-01

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 153 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-12-31
• Study Completion Date: 2015-05-31

Brief Summary

A single-center, randomized, controlled, switching, open-label, parallel cohort study. Smoking subjects will be confined to a clinic for 9 days. During their stay, baseline assessments during ad libitum smoking will occur for the first 3 days. Following baseline, subjects will be switched to either an Electronic Cigarette or Nicotine Gum, and post-product switch assessments will occur for 6 days.

Conditions

Smoking

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: NONE

Study Groups

Usual Brand (UB) Cigarettes

Usual Brand Cigarette

Group Type: ACTIVE_COMPARATOR

Usual Brand Cigarette

Intervention Type: OTHER

Combustible cigarette brand style smoked most frequently by subject

Electronic Cigarette #1

VUSE® (original flavor, 29 mg nicotine)

Group Type: EXPERIMENTAL

Electronic Cigarette #1

Intervention Type: OTHER

Electronic cigarette

Electronic Cigarette #2

VUSE® (menthol flavor, 26 mg nicotine)

Group Type: EXPERIMENTAL

Electronic Cigarette #2

Intervention Type: OTHER

Electronic cigarette

Leading U.S. Nicotine Gum

4 mg nicotine polacrilex gum

Group Type: EXPERIMENTAL

Leading U.S. Nicotine Gum

Intervention Type: OTHER

4 mg nicotine polacrilex gum

Interventions

Usual Brand Cigarette

Combustible cigarette brand style smoked most frequently by subject

Intervention Type: OTHER

Electronic Cigarette #1

Electronic cigarette

Intervention Type: OTHER

Electronic Cigarette #2

Electronic cigarette

Intervention Type: OTHER

Leading U.S. Nicotine Gum

4 mg nicotine polacrilex gum

Intervention Type: OTHER

Other Intervention Names

UB Cigarette; VUSE® Digital Vapor Cigarette (original flavor, 29 mg nicotine); VUSE® Digital Vapor Cigarette (menthol flavor, 26 mg nicotine)

Eligibility Criteria

Inclusion Criteria

1. Able to read, understand, and willing to sign an Informed Consent Form (ICF) and complete questionnaires written in English;

2. Generally healthy males or females, 21 to 60 years of age (inclusive);

3. Screening expired-air carbon monoxide (ECO) level ≥ 15 parts per million (ppm; sample taken 30 to 60 minutes after smoking a single UB cigarette);

4. Currently smokes combustible, filtered, nonmenthol or menthol cigarettes, 83 mm to 100 mm length;

5. Self-reports that cigarettes are the only tobacco or nicotine-containing product used within 30 days of the Screening Visit;

6. Self-reports at the Screening Visit smoking at least 10 cigarettes per day and inhaling the smoke for at least 6 months prior to the Screening Visit;

7. Response to Fagerström Test for Nicotine Dependence (FTND) Question 1 ("How soon after you wake up do you smoke your first cigarette?") is either "Within 5 minutes" or "6-30 minutes" at the Screening Visit;

8. Positive urine cotinine test at Screening and Enrollment;

9. Willing to switch from current cigarette to VUSE Digital Vapor Cigarettes or nicotine gum for 6 days during in-clinic confinement (nonmenthol smokers willing to switch to VUSE Original Digital Vapor Cigarettes or nicotine gum; menthol smokers willing to switch to VUSE Menthol Digital Vapor Cigarettes or nicotine gum);

10. Willing to abstain from tobacco and nicotine use for at least 12 hours twice during confinement;

11. Willing to not participate for 60 days poststudy in donation of blood samples or in any study that requires collection of blood samples;

12. Females of childbearing potential must be willing to use a form of contraception acceptable to the Investigator from the time of signing the ICF until Study Discharge or be surgically sterile for at least 90 days prior to the Screening Visit;

13. Able to safely perform the required study procedures, as determined by the Investigator.

Exclusion Criteria

1. Clinically significant or unstable/uncontrolled acute or chronic medical conditions at screening, as determined by the Investigator, that would preclude a subject from participating safely in the study (eg, hypertension, asthma, or other lung disease, cardiac disease, neurological disease, or psychiatric disorders) based on screening assessments such as safety labs, medical history, and physical/oral examinations;

2. Self-reports or safety labs indicate diabetes;

3. Self-reports stomach ulcers;

4. At risk for heart disease, as determined by the Investigator;

5. Use of medicine for treatment of depression or asthma;

6. Systolic blood pressure of ≥ 150 mmHg or a diastolic blood pressure of ≥ 95 mmHg, measured after being seated for 5 minutes;

7. Positive test for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C virus antibody (anti-HCV);

8. Hemoglobin level is < 12 g/dL at Screening:

9. History or presence of hemophilia or any other bleeding disorders:

10. History or presence of clotting disorders with concomitant use of anticoagulants (eg, clopidogrel [Plavix®], warfarin [Coumadin®, Jantoven®], and aspirin [> 325 mg/day]);

11. Given a whole blood donation within 8 weeks (≤ 56 days) prior to Enrollment;

12. Plasma donation within (≤) 7 days prior to Enrollment;

13. Weight of ≤ 110 pounds;

14. Poor peripheral venous access;

15. Postponing a decision to quit smoking (defined as planning a quit attempt within 30 days of Screening) to participate in this study;

16. Employed by a tobacco company, the clinical site, or handles unprocessed tobacco as part of his/her job;

17. Use of marijuana-based materials within 30 days prior to screening;

18. Use of any medication or supplement that aids smoking cessation, including but not limited to any NRT (eg, nicotine gum, lozenge, patch), varenicline (Chantix®), bupropion (Wellbutrin®, Zyban®), or lobelia extract within 30 days of the Screening Visit;

19. Use of injectable forms of medication(s), with the exception of injectable forms of birth control that are not required to be administered during the study period.

20. Self-reports drinking more than 14 servings of alcoholic beverages per week (1 serving = 12 oz of beer, 6 oz of wine, or 1 oz of liquor);

21. Females who have a positive pregnancy test, are pregnant, breastfeeding, or intend to become pregnant during the course of the study;

22. Females ≥ 35 years of age currently using systemic, estrogen-containing contraception, or hormone replacement therapy;

23. A positive urine drug screen without disclosure of corresponding prescribed concomitant medication(s) at the Screening Visit or Enrollment;

24. A positive alcohol breathalyzer test at Screening or Enrollment;

25. Regularly exposed to solvent fumes or gasoline (eg, painter, gas station mini-mart employee, etc.);

26. Determined by the Investigator to be inappropriate for this study, including a subject who is unable to communicate or unwilling to cooperate with the clinical staff;

27. Unable or unwilling to participate in the in-clinic confinement for the full study duration (total of 9 days).

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Davita Clinical Research

INDUSTRY

Sponsor Role: collaborator

RAI Services Company

INDUSTRY

Sponsor Role: collaborator

R.J. Reynolds Vapor Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Harry Alcorn, Jr., PharmD

Role: PRINCIPAL_INVESTIGATOR

Davita Clinical Research

Locations

DaVita Clinical Research

Minneapolis, Minnesota, United States

Countries

United States

Other Identifiers

CSD1304

Identifier Type: -

Identifier Source: org_study_id